Nobivac® KC

Nobivac® KC

A live vaccine against canine infectious tracheobronchitis caused by B. bronchiseptica and parainfluenza virus in dogs.


Nobivac KC

Live vaccine for dogs containing attenuated Bordetella bronchiseptica and canine parainfluenza virus for intranasal application.

This product may only be prescribed by your veterinary practitioner from whom advice must be sought.

Infectious tracheobronchitis is a highly contagious, multi-factorial disease of the dog’s respiratory tract. Bordetella bronchiseptica and canine parainfluenza are the most common bacterial and viral agents associated with the disease. Environmental factors such as stress, ventilation and climate may also contribute.

Nobivac KC is a low volume dose (0.4ml), easy to administer, intranasal vaccine which acts against both the key causative agents of infectious tracheobronchitis and provides protection within 72 hours and lasts for at least 12 months. It can be used in puppies as young as three weeks and in pregnant bitches. For uses, dosage, contra-indications and warnings please consult product leaflet. Use medicines responsibly.

Active Ingredients
A live attenuated freeze-dried vaccine containing Bordetella bronchiseptica and canine parainfluenza virus.

For the active immunisation of dogs against B. bronchiseptica and canine parainfluenza virus, aiding in the protection against canine cough.

  • Immunity is achieved as early as 72 hours after vaccination for bronchiseptica and 3 weeks for canine parainfluenza.
  • The components of Nobivac KC have been shown to protect against canine kennel cough caused by  bronchiseptica and parainfluenza virus for at least 12 months.
  • Nobivac KC can be used in pregnant bitches.
  • Nobivac KC is safe for use in pups from 2 weeks of age.

Reconstitute each single dose vial with one vial (0.4ml) of Nobivac KC diluent. Administer entire contents into a single nostril only.

Packaging Quantities

Cartons of 5 or 25 single dose vials with diluent. Not all pack sizes may be marketed.

MSD Product